全文获取类型
收费全文 | 1438篇 |
免费 | 43篇 |
国内免费 | 4篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 27篇 |
妇产科学 | 18篇 |
基础医学 | 89篇 |
口腔科学 | 11篇 |
临床医学 | 64篇 |
内科学 | 728篇 |
皮肤病学 | 6篇 |
神经病学 | 82篇 |
特种医学 | 72篇 |
外科学 | 179篇 |
综合类 | 8篇 |
预防医学 | 36篇 |
眼科学 | 4篇 |
药学 | 85篇 |
肿瘤学 | 65篇 |
出版年
2023年 | 7篇 |
2022年 | 6篇 |
2021年 | 30篇 |
2020年 | 14篇 |
2019年 | 26篇 |
2018年 | 30篇 |
2017年 | 10篇 |
2016年 | 12篇 |
2015年 | 20篇 |
2014年 | 60篇 |
2013年 | 55篇 |
2012年 | 74篇 |
2011年 | 84篇 |
2010年 | 36篇 |
2009年 | 33篇 |
2008年 | 59篇 |
2007年 | 87篇 |
2006年 | 73篇 |
2005年 | 91篇 |
2004年 | 80篇 |
2003年 | 73篇 |
2002年 | 78篇 |
2001年 | 49篇 |
2000年 | 54篇 |
1999年 | 36篇 |
1998年 | 12篇 |
1997年 | 15篇 |
1996年 | 5篇 |
1995年 | 8篇 |
1994年 | 6篇 |
1993年 | 7篇 |
1992年 | 20篇 |
1991年 | 20篇 |
1990年 | 28篇 |
1989年 | 25篇 |
1988年 | 25篇 |
1987年 | 13篇 |
1986年 | 18篇 |
1985年 | 18篇 |
1984年 | 11篇 |
1983年 | 10篇 |
1982年 | 13篇 |
1981年 | 7篇 |
1979年 | 6篇 |
1978年 | 7篇 |
1977年 | 3篇 |
1975年 | 3篇 |
1974年 | 7篇 |
1969年 | 3篇 |
1963年 | 3篇 |
排序方式: 共有1485条查询结果,搜索用时 593 毫秒
71.
Zhang YC Molano RD Pileggi A Powers M Cross J Wasserfall C Scott-Jorgensen M Campbell-Thompson M Crawford JM Flotte T Ellis TM Ricordi C Atkinson MA Inverardi L 《Transplantation》2002,74(8):1184-1186
Previous studies suggest that therapeutic expression of interleukin (IL)-4 by islet cells improves their efficacy in transplantation models directed at reversing type 1 diabetes. We investigated the effects of introducing IL-4 into islets with recombinant adeno-associated virus (rAAV) on the reversal of hyperglycemia in a syngeneic marginal islet mass transplantation model. C57BL/6 islets were mock-transduced or transduced with rAAV expressing murine IL-4 (rAAV-IL-4) or rAAV expressing green fluorescent protein (rAAV-GFP) before transplantation of a marginal mass into diabetic mice. Normoglycemia was achieved in only 1/7 mice receiving rAAV-IL-4 transduced islets in comparison to 6/6 mock-transduced and 4/6 rAAV-GFP transduced animals. The failure of IL-4 expressing islets was not associated with cellular toxicity of rAAV or impairment of glucose-stimulated insulin release in vitro. Islet expression of IL-4 led to impaired metabolic function in mice receiving a marginal mass of syngeneic islets. 相似文献
72.
73.
74.
Shimbo D Osende J Chen J Robbins J Shimoto Y Kunitada S Fuster V Badimon JJ 《Thrombosis and haemostasis》2002,88(5):733-738
BACKGROUND: Recent evidence suggests that TF may play a causal role in acute coronary syndromes, and may be an important therapeutic target. Several inhibitors of TF, coagulation factors VIIa and Xa are under investigation as novel antithrombotic approaches. We compared the antithrombotic effects of DX-9065a, a new FXa inhibitor, vs. enoxaparin. METHODS AND RESULTS: The protocol was an open-label crossover study. Subjects (n = 6) participated in 3 consecutive study-arms: a) enoxaparin + ASA (1 mg/Kg s. c + 162 mg/day x 3 days), b) three escalating doses of DX-9065a (1 mg bolus + 0.25 mg/h x 2 h, followed by an additional 1 mg bolus + 0.625 mg/h x 2 h and, a final 1 mg bolus + 1.25 mg/h x 2 h), and c) the same doses of DX-9065a in Arm 2 plus ASA pre-treatment. The antithrombotic effects were assessed using the Badimon perfusion chamber at each dose level. The administration of DX-9065a whether alone or combined with ASA significantly inhibited thrombus formation at high and low shear rate conditions while enoxaparin did not have a significant effect. Furthermore, these antithrombotic effects were obtained without significant prolongations of the standard coagulation parameters as those induced by enoxaparin. CONCLUSIONS: The direct inhibition of FXa by DX-9065a appears to be a safe and effective new approach for preventing the thrombotic complications of atherosclerotic disease. The clinical effectiveness of the direct FXa inhibitors should be further investigated. 相似文献
75.
Gregoratos G Abrams J Epstein AE Freedman RA Hayes DL Hlatky MA Kerber RE Naccarelli GV Schoenfeld MH Silka MJ Winters SL Gibbons RI Antman EM Alpert JS Hiratzka LF Faxon DP Jacobs AK Fuster V Smith SC;American College of Cardiology/American Heart Association Task Force on Practice Guidelines American College of Cardiology/American Heart Association/North American Society for Pacing Electrophysiology Committee 《Journal of cardiovascular electrophysiology》2002,13(11):1183-1199
76.
Prefrontal neurons in networks of executive memory 总被引:5,自引:0,他引:5
Fuster JM 《Brain research bulletin》2000,52(5):331-336
The neuronal networks of the frontal lobe that represent motor or executive memories are probably the same networks that cooperate with other cerebral structures in the temporal organization of behavior. The prefrontal cortex, at the top of the perception-action cycle, plays a critical role in the mediation of contingencies of action across time, an essential aspect of temporal organization. That role of cross-temporal mediation is based on the interplay of two short-term cognitive functions: one retrospective, of short-term active perceptual memory, and the other prospective, of attentive set (or active motor memory). Both appear represented in the neuronal populations of dorsolateral prefrontal cortex. At least one of the mechanisms for the retention of active memory of either kind seems to be the reentry of excitability through recurrent cortical circuits. With those two complementary and temporally symmetrical cognitive functions of active memory for the sensory past and for the motor future, the prefrontal cortex seems to secure the temporal closure at the top of the perception-action cycle. 相似文献
77.
78.
Fuster D Herranz R Alcover J Mateos JJ Martín F Vidal-Sicart S Pons F 《Revista espanola de medicina nuclear》2000,19(4):270-274
This study has aimed to evaluate the usefulness of repeated treatment with 89Sr in patients with prostate neoplasm and metastatic bone pain. Seventeen patients with partial or complete response after the first dose were retreated with two or more doses (total of 39 doses). The Karnofsky functional status, pain and degree of analgesia were assessed. After the first dose the response was good in 68% of the patients and partial in 32%. After the second dose, the response was good in 62% of the patients, partial in 15% and there was no response in 23% of the cases. The pre-treatment Karnofsky functional status and duration of the effect of 89Sr was lower after the second dose (p = 0.03, p = 0.02), but there were no statistically significant differences in the type of response. In conclusion, re-treatment with 89Sr can be administered safely and with a similar response to that achieved after the first dose. 相似文献
79.